# Pembrolizumab + Poly-ICLC in MRP Colon Cancer

> **NCT02834052** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asha Nayak** · enrollment: 42 (actual)

## Conditions studied

- Metastatic Colon Cancer
- Solid Tumor

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** Poly-ICLC

## Key facts

- **NCT ID:** NCT02834052
- **Lead sponsor:** Asha Nayak
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-10
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-07-29
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834052, "Pembrolizumab + Poly-ICLC in MRP Colon Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02834052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*